Browsing by Issue Date, starting with "2014"
Now showing 1 - 10 of 196
Results Per Page
Sort Options
- Abordagem Nutricional e Dietética na Prevenção e Tratamento da Hipertensão ArterialPublication . Mendes, D; Marques da Silva, P
- Multidrug-Resistant Klebsiella Pneumoniae Meningitis Successfully Treated with Intrathecal ColistinPublication . Furtado, F; Figueiredo, I; Iraneta, A; Matos, M; Gouveia, C; Varandas, LBackground: Multidrug-resistant (MDR) gram negative bacteria meningitis has become a clinical entity with increasing importance in recent years. Intrathecal colistin (ITH) has been used in the treatment of this cases. Aims: To report one case of MDR Klebsiella pneumoniae meningitis and ventriculitis successfully treated with ITH colistin. Case Report: Nine months old boy, born at 28 weeks of gestational age, diagnosed with neonatal meningitis, complicated with tetraventricular hydrocephalus requiring ventriculo-peritoneal shunt (VPS) placement and multiple shunt revisions. Admitted for worsening hydrocephalus. Cerebrospinal fluid (CSF) cultures were positive for extended-spectrum β-lactamase (ESBL) Klebsiella pneumoniae, only sensitive to meropenem and amikacin. Intravenous meropenen was started but CSF cultures remained positive and shunt device could not be removed. Although susceptibility to colistin was not available, on day 24 intrathecal colistin(4mg/day) was started through an external shunt. CSF white blood cell count improved and cultures became negative. Colistin was stopped after 19 days because of CSF pleocitosis and meropenen maintained for a total of 2 months with clinical improvement. Conclusion: In Klebsiella pneumoniae meningitis with ventriculitis, ITH colistin can be considered a safe, effective, and practicable alternative treatment when parental administration fails.
- The Role of Propranolol in the Treatment of Infantile HemangiomaPublication . Laranjo, S; Costa, G; Paramés, F; Freitas, I; Martins, JD; Trigo, C; Pinto, MFINTRODUCTION: Infantile hemangioma (IH) is one of the most common childhood tumors. There are various medical or surgical therapeutic options, all with suboptimal results. Recently, the successful use of propranolol for involution of IH was described. We report the results of a single-center experience with this therapeutic option. OBJECTIVE: To prospectively assess the efficacy and safety of propranolol in children with infantile hemangioma. METHODS: We performed a prospective analysis of clinical data of all patients with IH referred to a pediatric cardiology center for baseline cardiovascular assessment prior to propranolol therapy. Propranolol was given at a starting dose of 1 mg/kg/day and titrated to a target dose of 2-3 mg/kg/day according to clinical response. Efficacy was assessed through a photograph-based severity scoring scale. Safety was assessed by collecting data regarding significant side effects. RESULTS: Starting in 2010, 30 patients (15 female) were referred for propranolol treatment of IH, at a median age of six months (1-63 months). The mean target propranolol dose was 2.8 mg/kg/day, with a mean duration of therapy of 12 months. All patients experienced significant reduction of IH size and volume. There were no side effects. CONCLUSIONS: In our experience propranolol appears to be a useful and safe treatment option for severe or complicated IH, achieving a rapid and significant reduction in their size. No adverse effects were observed, although until larger clinical trials are completed, potential adverse events should be borne in mind and consultation with local specialists is recommended prior to initiating treatment.
- Doença de Kawasaki e Fleimão Retrofararíngeo: Uma Doença?Publication . Garcia, AM; Laranjo, S; Pinto, F; Gouveia, C; Varandas, L
- Optimal Cut-Off Value for Homeostasis Model Assessment (HOMA) Index of Insulin-Resistance in a Population of Patients Admitted Electively in a Portuguese Cardiology WardPublication . Timóteo, AT; Miranda, F; Mota Carmo, M; Cruz Ferreira, RINTRODUCTION: Insulin resistance is the pathophysiological key to explain metabolic syndrome. Although clearly useful, the Homeostasis Model Assessment index (an insulin resistance measurement) hasn't been systematically applied in clinical practice. One of the main reasons is the discrepancy in cut-off values reported in different populations. We sought to evaluate in a Portuguese population the ideal cut-off for Homeostasis Model Assessment index and assess its relationship with metabolic syndrome. MATERIAL AND METHODS: We selected a cohort of individuals admitted electively in a Cardiology ward with a BMI < 25 Kg/m2 and no abnormalities in glucose metabolism (fasting plasma glucose < 100 mg/dL and no diabetes). The 90th percentile of the Homeostasis Model Assessment index distribution was used to obtain the ideal cut-off for insulin resistance. We also selected a validation cohort of 300 individuals (no exclusion criteria applied). RESULTS: From 7 000 individuals, and after the exclusion criteria, there were left 1 784 individuals. The 90th percentile for Homeostasis Model Assessment index was 2.33. In the validation cohort, applying that cut-off, we have 49.3% of individuals with insulin resistance. However, only 69.9% of the metabolic syndrome patients had insulin resistance according to that cut-off. By ROC curve analysis, the ideal cut-off for metabolic syndrome is 2.41. Homeostasis Model Assessment index correlated with BMI (r = 0.371, p < 0.001) and is an independent predictor of the presence of metabolic syndrome (OR 19.4, 95% CI 6.6 - 57.2, p < 0.001). DISCUSSION: Our study showed that in a Portuguese population of patients admitted electively in a Cardiology ward, 2.33 is the Homeostasis Model Assessment index cut-off for insulin resistance and 2.41 for metabolic syndrome. CONCLUSION: Homeostasis Model Assessment index is directly correlated with BMI and is an independent predictor of metabolic syndrome.
- Gynaecological issues in Adolescence Do Paediatricians and Paediatric Residents feel comfortable about it?Publication . Bota, S; Sassetti, L; Alcafache, M
- The HIF1A Functional Genetic Polymorphism at Locus +1772 Associates with Progression to Metastatic Prostate Cancer and Refractoriness to Hormonal CastrationPublication . Fraga, A; Ribeiro, R; Príncipe, P; Lobato, C; Pina, F; Maurício, J; Monteiro, C; Sousa, H; Calais da Silva, F; Lopes, C; Medeiros, RThe hypoxia inducible factor 1 alpha (HIF1a) is a key regulator of tumour cell response to hypoxia, orchestrating mechanisms known to be involved in cancer aggressiveness and metastatic behaviour. In this study we sought to evaluate the association of a functional genetic polymorphism in HIF1A with overall and metastatic prostate cancer (PCa) risk and with response to androgen deprivation therapy (ADT). The HIF1A +1772 C>T (rs11549465) polymorphism was genotyped, using DNA isolated from peripheral blood, in 1490 male subjects (754 with prostate cancer and 736 controls cancer-free) through Real-Time PCR. A nested group of cancer patients who were eligible for androgen deprivation therapy was followed up. Univariate and multivariate models were used to analyse the response to hormonal treatment and the risk for developing distant metastasis. Age-adjusted odds ratios were calculated to evaluate prostate cancer risk. Our results showed that patients under ADT carrying the HIF1A +1772 T-allele have increased risk for developing distant metastasis (OR, 2.0; 95%CI, 1.1-3.9) and an independent 6-fold increased risk for resistance to ADT after multivariate analysis (OR, 6.0; 95%CI, 2.2-16.8). This polymorphism was not associated with increased risk for being diagnosed with prostate cancer (OR, 0.9; 95%CI, 0.7-1.2). The HIF1A +1772 genetic polymorphism predicts a more aggressive prostate cancer behaviour, supporting the involvement of HIF1a in prostate cancer biological progression and ADT resistance. Molecular profiles using hypoxia markers may help predict clinically relevant prostate cancer and response to ADT.
- Probióticos para Prevenção de Enterocolite Necrosante em Recém-Nascidos Pré-TermoPublication . Correia, M; Fernandes, RM; Neto, MT; Cordeiro Ferreira, G
- Benign Acute Childhood Myositis: an Alarming Condition With an Excellent Prognosis!Publication . Santos, J; Albuquerque, C; Lito, D; Cunha, F
- Herpes Simplex Encephalitis Does Interferon Care?Publication . Painho, T; Vieira, JP; Silva, R; Conceição, C; Casanova, JL; Brito, MJIntroduction and aims: Herpes simplex encephalitis (HSE) is an acute, life-threatening disease, requiring prompt intervention. TLR3-interferon (IFN) axis defects in the antiviral innate immune response against HSV-1 and some genes (TLR3, UNC93B1 and TRAF3) probably play an important role in HSE pathogenesis. Methods: Descriptive study between January 2007 and December 2012 from HSE patients treated with acyclovir (initiated between D2 to D3 of illness) and INF alpha-2b. HSV-1 was detected by PCR from CSF. PBMC and fibroblasts were studied for their IFN responses to TLR3 and virus stimulations. Coding exons of the known HSE-associated genes were sequenced. Results: Six cases, aged between 7 months and 11 years, with seizures and extensive brain injury. Interferon was initiated between D3 and D18. Patient 1 initiated IFN on D18 and stopped 7 days later for bicytopenia. Patient 2 started on D3 and has no sequelae. Patient 4 started on D5 and has persistent right sided hemiparesis. Patient 3, 5 and 6 started on D5, D3 and D7 respectively remain with epilepsy under medical control. Only Patient 1, who started IFN later than D7, has sequelar tetraparesis. None of the other patients have severe neurological deficits. The functional studies were normal, except for patient 1 whose fibroblasts displayed impaired IFN-lambda production after stimulations of poly(I:C), thought to be TLR3-dependent. No mutation was found in the sequenced coding exons of UNC93B1, TLR3 and TRAF3. Conclusions: Although a small sample, our results suggest that IFN therapy should be considered in the treatment of HSE.